AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma

    NEXT STORY
    SEngine Precision Medicine’s PARIS® Test Identifies Novel Drug Combinations for PARP Inhibitor Resistant Ovarian Cancer in Study Published in EBioMedicine
    PREV STORY
    Theranostics: Global Markets
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Ziopharm Oncology Reports First Quarter 2019 Financial Results and Reaffirms Clinical Timelines

    author_avatar
    NASDAQ Market News

    Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years

    CAMBRIDGE, Mass., March 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in ...

    author_avatar
    NASDAQ Market News

    Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth

    - Incoming specialists to focus on Quality Control and Quality Assurance Aspects of Supply ...

    author_avatar
    NASDAQ Market News